Search
Propylthiouracil
go.drugbank.com/drugs/DB00550ApprovedPropythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism.
Synonyms: 2-Mercapto-6-propylpyrimid-4-one, 2-Thio-6-propyl-1,3-pyrimidin-4-oneIobitridol
go.drugbank.com/drugs/DB12407ApprovedWithdrawnIobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.
Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household settingTisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigational[A238914] On September 20, 2021, the FDA granted accelerated approval to tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer in adults in whom the disease progressed during … Each monoclonal antibody molecule carries an average of four MMAE molecules. Tisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalIt was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Edaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigational[L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. … [A19140,L44007,A254257] The intravenous formulation of edaravone was first approved in Japan in 2001 for the treatment of acute ischemic stroke.
Synonyms: 3-methyl-1-phenylpyrazol-5-one, 3-methyl-1-phenyl-2-pyrazolin-5-oneCategories: Compounds used in a research, industrial, or household settingPhysostigmine
go.drugbank.com/drugs/DB00981ApprovedIt also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.
Dasabuvir
go.drugbank.com/drugs/DB09183Approved12 weeks or 24 weeks of treatment including [DB00811]. … SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma
Synonyms: N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamideCategories: Antivirals for treatment of HCV infections, Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase InhibitorTirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigational[A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin.
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalIt is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis and … Epclusa is the first combination HCV product indicated for the treatment of all genotypes of Hepatitis C with or without cirrhosis.
Categories: Antivirals for treatment of HCV infectionsCyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnCyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.